pgµç×Ó¹ÙÍø

±±¾©»ùÒò×éËù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©ÏàÖú½Òʾ¶ùͯ°×Ѫ²¡¸É/×æϸ°ûµÄÒìÖÊÐÔ¼°»¯ÁÆÄÍÒ©µÄ¸Éϸ°ûÑÇȺ

¡¡¡¡¼±ÐÔËèϵ°×Ѫ²¡£¨acute myeloid leukemia, AML£©ÊÇÒ»ÖÖ¶ñÐÔѪҺÖ×Áö£¬Í¨³£ÓÉÓÚËèϵÔìѪ¸É/×æϸ°ûÆÊÎöÊÜ×è¶øÒýÆð¡£AML²¡³Ì½øչѸËÙ¡¢ÖÎÓúÂʽϵÍ¡£¾Ýͳ¼Æ£¬¶ùͯ»¼ÕßµÄÎåÄêÎÞ²¡Éú´æÂʽöÔ¼50%¡£»¯ÁÆÊÇAMLµÄÖ÷ÒªÖÎÁÆÒªÁìÖ®Ò»£¬ÄÜÏÔÖø¼õÉÙÖ×Áöϸ°ûÊýÁ¿£¬Ê¹»¼Õߵִﻺ½â£¬µ«ÈÔÓÐһС²¿·ÖÖ×Áöϸ°û²ÐÁô£¬¿ÉÄܳÉΪÒýÆð¼²²¡¸´·¢µÄÖÖ×Ó¡£ËäÈ»»ùÓÚ»ùÒòÍ»±äµÄÒªÁì¿ÉÒÔÁéÃôµØ¼ì²â²ÐÁôϸ°û£¬µ«Òª½âÎö»º½âÆÚ²ÐÁôµÄ°×Ѫ²¡Ï¸°ûµÄÉúÎïѧÌØÐÔÈ´ÃæÁÙ¾Þ´óÌôÕ½¡£ÁÙ´²ÉÏҲһֱȱ·¦ÌØÒìÐÔµÄÒªÁìÓÃÓÚÕï¶Ï¡¢¼à²âºÍÇå³ýÕâЩϸ°û¡£

¡¡¡¡¾Û½¹ÓÚÉÏÊöÁÙ´²ÎÊÌ⣬pgµç×Ó¹ÙÍø£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©ÍõÇ°·ÉÍŶÓÓëËÕÖÝ´óѧÁ¥Êô¶ùͯҽԺµÄºúÉÜÑàÍŶÓÏàÖú£¬ÒÀÍÐÓÚ¶ùͯAMLµÍ¼ÁÁ¿»¯ÁÆÁªºÏG-CSFÈýÆÚËæ»ú±ÈÕÕ¶àÖÐÐÄÁÙ´²ÊÔÑé(CALS III-AML18)£¬Í¨¹ý¾«Ï¸½âÎö»¼Õß»¯ÁÆÇ°ºó¹ÇËèµÄÒìÖÊÐÔϸ°ûȺÌ壬²¢½áºÏÁÙ´²´óÑù±¾ÐÐÁÐÑéÖ¤ºÍ¹¦Ð§ÊµÑ飬Ê״ο̻­Á˶ùͯAML»¯Áƺó²ÐÁôÖ×Áöϸ°ûµÄµ¥Ï¸°ûת¼×éͼÆס£¸ÃÑо¿Ã÷È·ÁË»¼ÕßÌåÄڵİ×Ѫ²¡¸Éϸ°û£¨leukemia stem cell, LSC£©ºÍÑõ»¯Á×Ëữ(oxidative phosphorylation, OXPHOS)Á½¸öÄÍÒ©ÌØÕ÷¼°Æä¶ÔÓ¦µÄ¾«È·Ï¸°ûÑÇȺ£¬·¢Ã÷ÁËÄÍÒ©µÄHSC-like¸Éϸ°ûÑÇȺ¼°ÆäÍâò±ê¼ÇÎïCD69£¬²¢¿ª¶Ë½ÒʾÁËCD69ͨ¹ýµ÷¿ØmTOR-CCND1-CXCR4Öá½éµ¼ÄÍÒ©µÄ·Ö×Ó»úÖÆ¡£Ñо¿»¹·¢Ã÷¸Ã¸Éϸ°ûÄÍÒ©ÑÇȺµÄϸ°û±ÈÀý¸ßÓëÔ¤ºó²»Á¼µÄÁÙ´²±íÐͺͻùÒò×éÌØÕ÷Ïà¹Ø¡£ÕâЩÈÏʶΪÁÙ´²Õï¶ÏºÍ¼à²âÌṩÁËÖØÒªµÄÀíÂÛÒÀ¾Ý¡£¸Ã½á¹ûÒÔ¡±Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML¡±ÎªÌ⣬ÓÚ2023Äê8ÔÂ31ÈÕÐû²¼ÔÚGenome Biology ÆÚ¿¯¡£

¡¡¡¡pgµç×Ó¹ÙÍø£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©ÍõÇ°·ÉÑо¿Ô±¡¢ËÕÖÝ´óѧÁ¥Êô¶ùͯҽԺµÄºúÉÜÑàÖ÷ÈÎΪ±¾ÎĵÄÅäºÏͨѶ×÷Õߣ¬pgµç×Ó¹ÙÍø£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©²©Ê¿½áÒµÉú½­æ­æú͸±Ñо¿Ô±ºÍ·òºì£¬ÒÔ¼°ËÕÖÝ´óѧÁ¥Êô¶ùͯҽԺ²©Ê¿½áÒµÉúÕÅÓÀƽºÍ²©Ê¿ºóÌï԰԰ΪÎÄÕµÄÅäºÏµÚÒ»×÷Õß¡£¸ÃÑо¿»ñµÃÁ˿Ƽ¼²¿ÖصãÑз¢¼Æ»®¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢½­ËÕÊ¡¡¢pgµç×Ó¹ÙÍøµÈÏîÄ¿µÄ×ÊÖú¡£

PGµç×Ó¡¤(Öйú)¹Ù·½ÍøÕ¾

¶ùͯ°×Ѫ²¡¸É/×æϸ°ûµÄÒìÖÊÐÔ¼°»¯ÁÆÄÍÒ©µÄ¸Éϸ°ûÑÇȺ

¡¡¡¡ÂÛÎÄÁ´½Ó

¸½¼þÏÂÔØ£º
ÍøÕ¾µØͼ
ÓÑÇéÁ´½Ó£º¿­·¢¹ÙÍøÈë¿Ú  AGÕæÈ˹ú¼Ê  pgµç×Ó¹ÙÍø  À´Àû¹ú¼Êw66  8868ÌåÓý  AGÕæÈ˹ú¼Ê  J9¾ÅÓλᠠ3377ÌåÓý  Ç§ÒÚÇòÓѻᠠAGÆì½¢Ìü  AGÕæÈ˹ú¼Ê  AGÕæÈË  ÍòÏó³Ç¹ÙÍø  8868ÌåÓý¹ÙÍø  pgµç×Ó